RxDoctor Payments Data

Arturo Cedeno Llorens, MD

Pulmonary Disease · Aguadilla, PRNPI 1679577399

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AstraZeneca at 42.3% of the total.

$3,543in general payments, 2019–2025

Across 115 payments — averaging $30.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$433
  • Boehringer Ingelheim$421
  • Merck$291
  • Johnson & Johnson$289
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$94
  • plus $517 from 10 others

What the payments were for

  • Food & beverage$3,538100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,543 in reported general payments places this provider in the 60th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$5,318
Medicare patients
18
Services billed
75

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate11$144,508
Trelegy ElliptaFluticasone/Umeclidin/Vilanter124$82,641
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate221$63,049
Breztri AerosphereBudesonide/Glycopyr/Formoterol75$48,626
Breo ElliptaFluticasone/Vilanterol95$39,693
Spiriva RespimatTiotropium Bromide68$36,214
SymbicortBudesonide/Formoterol Fumarate115$27,432
Stiolto RespimatTiotropium Br/Olodaterol Hcl54$26,435
Albuterol Sulfate HfaAlbuterol Sulfate575$25,511
Wixela InhubFluticasone Propion/Salmeterol152$24,339
Fluticasone Propionate HfaFluticasone Propionate64$20,244
Spiriva HandihalerTiotropium Bromide21$10,838
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$9,206
Fluticasone-SalmeterolFluticasone Propion/Salmeterol49$6,349
Arnuity ElliptaFluticasone Furoate27$5,705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$421$207,157133 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$433$137,245266 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,498$76,058190 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Aguadilla

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →